Amarin Corp Plc (AMRN)

[ramfan60]

My suggestion to Elisabeth of Investor Relations back in April of 2020 and her response. If we change the formula to include a Statin, why not Corazon101?




Hi Steven- Interesting, but it would still be icosapent ethyl. I don’t think it would work. But I appreciate the out of the box thinking!

Elisabeth

Elisabeth Schwartz, Sr. Director of Investor Relations, Amarin Corporation plc
440 Route 22, Bridgewater, NJ 08807
Direct Number 908.326.2569
Email: [e-mail]



Sent: Wednesday, April 8, 2020 11:30 AM
To: [e-mail]
Subject: RE: Vascepa Commercials

Thanks Elisabeth............. I looking forward to seeing the ad and the continued success of Amarin and Vascepa.


Like everyone at Amarin, I was stunned by the patent judgement and certainly expect us to prevail on appeal. In the meantime I had this thought which is probably not at all possible for regulatory reasons but since I'm a simple human, here goes.

Amarin creates a new brand name just for the new indication "Corazon101". Corazon101 contains the same formula as Vascepa of course it's just a different brand name.

They still sell Vascepa brand for the old indication. So if we don't prevail in the appeal (which we will) we have:

Vascepa - lowers Trigs greater than 500.
Corazon101 - Reduces CV risks in patients with xyz

Generics then can only knock off the product called Vascepa. A pharmacy could suggest Generic for Vascepa yes but they couldn't suggest a Generic for Corazon101.

Is this possible?



Regards,

Steve